JAMA Cardiology 'Under Review': What Each Status Means

JAMA Cardiology's instructions say every submitted manuscript is read first by one of the editors and, if not rejected promptly, sent to expert consultants for single-anonymized peer review. The official medians show a materially faster first decision for papers not sent to external review than for papers that are, but a public status label does not prove which private task is active.

The instructions list the criteria editors apply: the material is original and timely, writing is clear, study methods are appropriate, data are valid, conclusions are supported by the data, the information is important, and the topic has general interest to readers of the journal. Work behind the label can leave the public label unchanged. Authors should therefore use dated messages and open tasks to decide what to do, while treating private reviewer direction, editor sentiment, and the precise next-decision date as unknown.

Before external review, one of the editors reads every submitted manuscript, and the instructions say manuscripts with insufficient priority for publication are rejected promptly. The current official JAMA Cardiology author page reports an 8% overall acceptance rate, but it does not establish what share of submissions leave at this specific portal stage or predict one manuscript's outcome.

The journal does not publish reasons for desk rejection. At submission, authors may choose to have a manuscript that is not accepted referred, with reviewers' comments if available, to another JAMA Network specialty journal and/or JAMA Network Open.

The instructions do not describe a separate administrative-check stage, so use them as the submission requirements: the manuscript file with title page, abstract, text, references, legends, and tables; figures as separate files; reporting checklists where applicable (CONSORT for clinical trials, STROBE for observational cardiology studies, PRISMA for systematic reviews, STARD for diagnostic-accuracy studies); a cover letter with the corresponding author's contact details and any related papers from the same study; ethics or institutional review board approval or waiver for studies of human participants or animals; trial registration (JAMA Network requires registered clinical trials); and, for randomized and nonrandomized clinical trials, the protocol with the statistical analysis plan. After submission, every author is sent a link to the Authorship Form, which covers conflict-of-interest disclosures.

One of the editors reads the paper against the criteria in the instructions: original and timely material, clear writing, appropriate study methods, valid data, conclusions supported by the data, importance, and general interest to readers of the journal. The journal's median to first decision without external peer review is 5 days (For Authors page, updated July 2026).

The instructions do not describe a separate statistical-review stage or say that clinical-trial submissions go to in-house statistical reviewers. They do require a protocol with a statistical analysis plan for randomized and nonrandomized clinical trials and set expectations for statistical methods and data presentation, and the masthead lists a Statistics Editor and a Consulting Statistical Editor.

Reviewer recruitment, active review, statistical assessment, and editorial synthesis can all leave the visible label unchanged. The current official 37-day median for a reviewed first decision is a portfolio reference, not a deadline. Prepare the reporting package and likely response points, but do not infer reviewer count, sentiment, or delay cause.

• An author task or technical inconsistency appears: respond or contact the office promptly.

• The elapsed time is materially beyond the current reviewed-decision median: check correspondence, then consider one neutral inquiry through the manuscript record.

• The label changes without a message: record the date and wait for the decision letter; do not infer sentiment.

Six weeks is longer than the current journal-level median for a reviewed first decision, but it does not identify the bottleneck or predict the result. Check correspondence and author tasks. If nothing explains the delay, a concise inquiry can name the manuscript ID, status date, and one concrete request for an update without asking for an acceptance prediction.

If your JAMA Cardiology paper is rejected after review, the natural cascade depends on what the reviewers and editor cited:

JAMA Network Open may be a useful JAMA Network route when its broader open-access scope fits. Follow the transfer option and timing shown in the actual decision letter rather than assuming reports or files will move on a fixed schedule.

Circulation is the AHA cascade option for cardiovascular papers where the broad-clinical-cardiology framing fits AHA's flagship clinical title. AHA operates independently; reports do not transfer, but Circulation editors may recognize JAMA Network reviewer reports informally.

Journal of the American College of Cardiology (JACC) is the ACC cascade option for cardiology papers with strong clinical-practice implications. ACC operates independently with its own reviewer pool.

European Heart Journal (EHJ) is the ESC cascade option for European-cardiology-focused work. ESC operates independently.

The instructions list the criteria editors use: original and timely material, clear writing, appropriate study methods, valid data, conclusions supported by the data, importance, and general interest to readers. The table below groups four preparation areas under those criteria; the grouping is Manusights judgment, not a journal checklist.

Use three manuscript checks before submission. The recurring issue is not only whether the trial or cohort is well run. It is whether the Key Points, first table, and statistical appendix let a clinical editor and statistical reviewer see the same decision without extra explanation.

CONSORT-compliance gaps surface as reviewer requests for clarification. When CONSORT checklist items are incomplete or trial-pre-registration alignment is unclear, reviewers and editors can be expected to ask for clarification. The strongest revisions add complete CONSORT documentation with pre-registration alignment.

Check your JAMA Network reporting package →

Statistical analysis plan under-documented. When the pre-specified statistical analysis plan is thin or post-hoc analyses are not clearly distinguished from pre-specified analyses, reviewers can be expected to request expanded methods documentation.

Check your statistical methods and SAP alignment →

Broad-clinical-consequence under-stated in framing. When the abstract and discussion do not clearly establish the broad-clinical decision that would change, editors and reviewers flag general-clinical-interest concerns. The strongest manuscripts frame the abstract around the specific cardiology decision the paper affects.

Check whether your clinical consequence is explicit →

Five preventable risks can be checked before peer review: a Key Points section that hides the clinical decision, incomplete reporting-checklist traceability, under-specified statistical analysis, weak data-sharing language, and a mismatch between JAMA Cardiology scope and a stronger JAMA Network Open or specialty-cardiology route.

Source limitation: official guidance explains submission rules and peer-review policy, but it cannot diagnose whether your abstract, Key Points, first table, methods appendix, reporting package, and cover letter satisfy JAMA Cardiology's broad-clinical-consequence bar.

This page was checked against JAMA Network public author guidance and the current JAMA Cardiology for-authors page on August 24, 2026. The official page supplies the 5-day and 37-day first-decision medians and 8% overall acceptance rate. The status interpretation and preparation checks are Manusights judgment, not private editorial data.

For the JAMA Network cardiology landscape beyond JAMA Cardiology, see JAMA Network Open (broader open-access), JAMA (top general-medicine), JAMA Internal Medicine (internal medicine focus), and sister cardiology titles (Circulation, JACC, EHJ). The choice across these titles depends on whether the central contribution is broad-clinical-cardiology (JAMA Cardiology), basic-cardiovascular (Circulation Research), AHA-clinical-practice (Circulation), ACC-clinical (JACC), or European-cardiology (EHJ).

Prepare a response template that separates clinical consequence, reporting integrity, and statistical-method questions. That structure can reduce author-side revision friction; it does not predict reviewer composition, timing, or outcome.

For a pre-upload check of your manuscript against the JAMA Cardiology broad-consequence-plus-statistical-rigor bar before submission, our JAMA Cardiology pre-submission diagnostic flags the CONSORT-compliance gaps and statistical-methodology weaknesses most likely to surface in reviewer reports.

Put each piece of status information into one of three categories. Known includes dated portal transitions and journal correspondence. Actionable includes files, forms, clarifications, or data the authors have been asked to provide. Unknown includes reviewer sentiment, editorial discussion, reviewer recruitment progress, and the likely outcome.

Resolve actionable items first and use known events to set a follow-up threshold. Leave unknown items out of the forecast. This simple separation prevents authors from overreacting to an unchanged label while still keeping the manuscript ready for a clinically focused revision. If the latest confirmed stage becomes materially atypical, send one neutral inquiry tied to the manuscript ID and date, asking whether the office needs anything further from the authors.

The visible status does not reveal the editor's judgment, but it does identify a useful preparation window. Check whether the clinical population, intervention or exposure, comparator, endpoints, analysis, harms, and interpretation form one consistent decision chain.

Prepare source tables, analysis code, registration/protocol references, and a response owner now. Do not draft a rebuttal to an imagined reviewer or treat the status label as acceptance evidence.